Europe Glp-1 Receptor Agonist Market Size & Outlook
Global Market
Related Markets
Europe glp-1 receptor agonist market highlights
- The Europe glp-1 receptor agonist market generated a revenue of USD 8,125.6 million in 2025.
- The market is expected to grow at a CAGR of 12.1% from 2026 to 2033.
- In terms of segment, semaglutide (ozempic, wegovy, rybelsus) was the largest revenue generating product in 2025.
- Tirzepatide (Mounjaro, Zepbound) is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 8,125.6 million |
| Market revenue in 2033 | USD 22,466.4 million |
| Growth rate | 12.1% (CAGR from 2026 to 2033) |
| Largest segment | Semaglutide (ozempic, wegovy, rybelsus) |
| Fastest growing segment | Tirzepatide (Mounjaro, Zepbound) |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound), Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Others (Byetta, Bydureon, SOLIQUA) |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Novo Nordisk A/S ADR, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, Europe region accounted for 12.2% of the global glp-1 receptor agonist market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Latin America is the fastest growing regional market and is projected to reach USD 5,715.7 million by 2033.
lucrative CAGR over the forecast period. This growth can be attributed to increased research funding and the presence of key market players in the region. In addition, rising investments are driving the number of biopharmaceutical companies in Europe.
The market for GLP-1 receptor agonists in Europe is experiencing significant growth, driven by an increasing prevalence of type 2 diabetes and a growing focus on obesity management. With diabetes affecting approximately 10% of the European adult population and obesity rates on the rise, the demand for effective treatments is expanding.
GLP-1 receptor agonists, known for their ability to improve glycemic control and support weight loss, are becoming a preferred choice among both healthcare providers and patients across the region. Furthermore, the market is experiencing a notable surge in demand due to various factors; for instance, in July 2024, the European drug authorities announced recommendations to address the growing shortages in GLP-1 receptor agonists.
No credit card required*
Publish Date: Dec 23, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Glenmark Pharmaceuticals | View profile | 10001+ | Andheri, Maharashtra, India, Asia | www.glenmarkpharma.com |
Europe GLP-1 Receptor Agonist Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to GLP-1 Receptor Agonist Market Outlook will help companies and investors design strategic landscapes.
Semaglutide (Ozempic, Wegovy, Rybelsus) was the largest segment with a revenue share of 72.72% in 2025.
Horizon Databook has segmented the Europe glp-1 receptor agonist market based on semaglutide (ozempic, wegovy, rybelsus), tirzepatide (mounjaro, zepbound), dulaglutide (trulicity), liraglutide (victoza, saxenda), others (byetta, bydureon, soliqua) covering the revenue growth of each sub-segment from 2021 to 2033.
lucrative CAGR over the forecast period. This growth can be attributed to increased research funding and the presence of key market players in the region. In addition, rising investments are driving the number of biopharmaceutical companies in Europe.
The market for GLP-1 receptor agonists in Europe is experiencing significant growth, driven by an increasing prevalence of type 2 diabetes and a growing focus on obesity management. With diabetes affecting approximately 10% of the European adult population and obesity rates on the rise, the demand for effective treatments is expanding.
GLP-1 receptor agonists, known for their ability to improve glycemic control and support weight loss, are becoming a preferred choice among both healthcare providers and patients across the region. Furthermore, the market is experiencing a notable surge in demand due to various factors; for instance, in July 2024, the European drug authorities announced recommendations to address the growing shortages in GLP-1 receptor agonists.
- Europe Glp-1 Receptor Agonist Market Product Outlook (Revenue, USD Million , 2021-2033)
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound)
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Others (Byetta, Bydureon, SOLIQUA)
- Europe Glp-1 Receptor Agonist Market Application Outlook (Revenue, USD Million , 2021-2033)
- Type 2 Diabetes Mellitus
- Obesity / Chronic Weight Management
- Cardiovascular Risk
- Europe Glp-1 Receptor Agonist Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Injectable / Parenteral
- Oral
- Europe Glp-1 Receptor Agonist Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to GLP-1 Receptor Agonist Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of GLP-1 Receptor Agonist Market Outlook databook
- Our clientele includes a mix of GLP-1 Receptor Agonist Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe GLP-1 Receptor Agonist Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe GLP-1 Receptor Agonist Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Glp-1 Receptor Agonist Market, 2021-2033 (US$M)
Europe glp-1 receptor agonist market statistics, by product, 2021-2033 (US$M)
